Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

Background It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …

Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …

For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary
syndrome (ACS) has been the only class I recommendation on DAPT in American and …

Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Importance Among patients undergoing percutaneous coronary intervention (PCI), it
remains unclear whether the treatment efficacy of P2Y 12 inhibitor monotherapy after a short …

Background The optimal duration of antiplatelet therapy (APT) after coronary stenting in
patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains …

Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …

Background Optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing
complex percutaneous coronary intervention (PCI) remains under investigation. Our aim is …